



Coding Systemic Therapy



Colon Cancer Systemic Therapy



Chemotherapy	Subcategory
Capecitabine (Xeloda)	Antimetabolite
Flourouracil (5-FU)	Antimetabolite
Irinotecan (Camptosar)	Topoisomerase inhibitor
Lonsurf (Trifluidine, Tipiracil)	None
Oxaliplatin (Eloxatin, Transplatin)	Platinum analog
Regorafenib (Stivarga)	Multi-kinase inhibitor
Zaltrap (Ziv-Aflibercept)	Angiogenesis inhibitor

Biological Response Modifiers	Subcategory
Bevacizumab (Avastin)	Cytostatic agent--antiangiogenesis agent
Cetuximab (Erbix)	Monoclonal antibody, anti-EGFR antibody
Cyramza (Ramucirumab)	Antiangiogenesis, Monoclonal antibody
Keytruda (Pembrolizumab)	monoclonal antibody
Nivolumab (Opdivo) FDA approved 8/17	braf inhibitor
Nivolumab (Opdivo) and Ipilimumab (Yervoy) approved 7/18	braf inhibitor & Monoclonal antibody
Panitumumab (Vectibix)	Cytostatic agent--monoclonal antibody

Common Regimens

FOLFOX: 5-FU, Oxaliplatin & Leucovorin*

FOLFOX + Avastin: 5-FU, Oxaliplatin, Leucovorin* and Avastin**

CAPOX or XELOX: Capecitabine, Oxaliplatin & Leucovorin*

FOLFIRI: 5-FU, Irinotecan & Leucovorin*

FOLFIRI + Avastin: 5-FU, Irinotecan, Leucovorin* & Avastin**

FOLFIRI + Cetuximab: 5-FU, Irinotecan, Leucovorin* & Cetuximab***

*Leucovorin: ancillary agent – **DO NOT CODE**

**Avastin: Biological Response Modifier

***Cetuximab: Biological Response Modifier

Adapted from the presentation "Coding Systemic Treatment" and used with permission of Mary B. Davidson, RN, BSN, MN, CTR